Growth hormone treatment, final height, insulin-like growth factors, ghrelin, and adiponectin in four siblings with Seckel syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 24, Issue 11-12, 2011, Pages 995-1000

  Birkebæk, Niels H ^a   Wolthers, Ole D ^b   Heuch, Carsten ^a   Balslev, Thomas ^c   Flyvbjerg, Allan ^a   Frystyk, Jan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Dytmarsken   (Denmark)

^c VIBORG HOSPITAL   (Denmark)

Author keywords

adiponectin subforms; bioactive IGF 1; ghrelin; growth hormone; IGF 1; IGFBP 3; seckel syndrome

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GHRELIN; HUMAN GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BODY MASS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; GROWTH RETARDATION; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; MALE; SECKEL SYNDROME; SIBLING; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADOLESCENT; BODY HEIGHT; CHILD; DWARFISM; FEMALE; GHRELIN; GROWTH CHARTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MICROCEPHALY; SIBLINGS; TREATMENT OUTCOME;

EID: 83655190850     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.2011.369     Document Type: Article

References (34)

1. Borglum AD, Balslev T, Haagerup A, Birkebaek N, Binderup H, et al. A new locus for Seckel syndrome on chromosome 18p11.31-q11.2. Eur J Hum Genet 2001;9:753-7. (Pubitemid 33014587)
2. Goodship J, Gill H, Carter J, Jackson A, Splitt M, et al. Autozygosity mapping of a seckel syndrome locus to chromosome 3q22. 1-q24. Am J Hum Genet 2000;67:498-503. (Pubitemid 30616752)
3. Kilinc MO, Ninis VN, Ugur SA, Tuysuz B, Seven M, et al. Is the novel SCKL3 at 14q23 the predominant Seckel locus? Eur J Hum Genet 2003;11:851-7. (Pubitemid 37406988)
4. Kjaer I, Hansen N, Becktor KB, Birkebaek N, Balslev T. Craniofacial morphology, dentition, and skeletal maturity in four siblings with Seckel syndrome. Cleft Palate Craniofac J 2001;38:645-51. (Pubitemid 33070634)
5. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, et al. Management of the child born small for ges-tational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007;92:804-10. (Pubitemid 46465644)
6. Ranke MB, Lindberg A. Growth hormone treatment of short children born small for gestational age or with Silver-Russell syndrome: results from KIGS (Kabi International Growth Study), including the fi rst report on fi nal height. Acta Paediatr Suppl 1996;417:18-26. (Pubitemid 27115738)
7. Collett-Solberg PF. Update in growth hormone therapy of children. J Clin Endocrinol Metab 2011;96:573-9.
8. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007;370:162-72. (Pubitemid 47044938)
9. Ramaswami U, Hindmarsh PC, Brook CG. Growth hormone therapy in hypochondroplasia. Acta Paediatr Suppl 1999;88:116-7. (Pubitemid 29108421)
10. Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007;92:10-25. (Pubitemid 46067503)
11. Ducos B, Cabrol S, Houang M, Perin L, Holzenberger M, et al. IGF type 1 receptor ligand binding characteristics are altered in a subgroup of children with intrauterine growth retardation. J Clin Endocrinol Metab 2001;86:5516-24. (Pubitemid 33070283)
12. Schmidt A, Chakravarty A, Brommer E, Fenne BD, Siebler T, et al. Growth failure in a child showing characteristics of Seckel syndrome: possible effects of IGF-I and endogenous IGFBP-3. Clin Endocrinol 2002;57:293-9. (Pubitemid 34989107)
13. Hertel NT, Hagenaes L. Seckel syndrome and GH therapy. The KIGS Experience. Horm Res 2004;62(Suppl 2):161.
14. Simic-Schleicher G. Seckel syndrome, somatotropin secretion and somatotropin therapy. Horm Res 2003;60(Suppl 2):48-9.
15. He Q, Albertsson-Wikland K, Karlberg J. Population-based body mass index reference values from G ö teborg, Sweden: birth to 18 years of age. Acta Paediatr 2000;89:582-92. (Pubitemid 30643421)
16. Wikland KA, Luo ZC, Niklasson A, Karlberg J. Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr 2002;91:739-54. (Pubitemid 34876160)
17. Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofl uorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 1995;5:169-76. (Pubitemid 26018330)
18. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, et al. A highly sensitive and specifi c assay for determination of IGF-I bio-activity in human serum. Am J Physiol Endocrinol Metab 2003;284:E1149-55. (Pubitemid 36617461)
19. Krassas G, Pontikides N, Dumas A, Frystyk J, Chen JW, et al. The effect of long-term somatostatin analogue treatment on free and total insulin-like growth factor (IGF)-I,-II and IGF binding protein-1,-2 and-3 serum levels in euthyroid patients with active thyroid eye disease. Hormones 2004;3:191-7.
20. Espelund U, Hansen TK, Hojlund K, Beck-Nielsen H, Clausen JT, et al. Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab 2005;90:741-6. (Pubitemid 40279189)
21. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005;48:1911-8. (Pubitemid 41317848)
22. Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007;92:1857-62. (Pubitemid 46997200)
23. Domene HM, Martinez AS, Frystyk J, Bengolea S V, Ropelato MG, et al. Normal growth spurt and fi nal height despite low levels of all forms of circulating insulin-like growth factor-I in a patient with acid-labile subunit defi ciency. Horm Res 2007;67:243-9. (Pubitemid 46558887)
24. Boscherini B, Iannaccone G, La CC, Mancuso G, Girotti F, et al. Intrauterine growth retardation. A report of two cases with bird-headed appearance, skeletal changes and peripheral GH resistance. Eur J Pediatr 1981;137:237-42. (Pubitemid 11031663)
25. Bachmann S, Bechtold S, Bonfig W, Putzker S, Buckl M, et al. Insulin sensitivity decreases in short children born small for gestational age treated with growth hormone. J Pediatr 2009;154:509-13.
26. Hale DE, Cody JD, Baillargeon J, Schaub R, Danney MM, et al. The spectrum of growth abnormalities in children with 18q deletions. J Clin Endocrinol Metab 2000;85:4450-4. (Pubitemid 32157617)
27. Auclair Y, Rouget R, Affar el B, Drobetsky EA. ATR kinase is required for global genomic nucleotide excision repair exclusively during S phase in human cells. Proc Natl Acad Sci USA 2008;105:17896-901.
28. Ong KK. Catch-up growth in small for gestational age babies: good or bad? Curr Opin Endocrinol Diabetes Obes 2007;14:30-4. (Pubitemid 46375385)
29. Gil-Campos M, Aguilera CM, Ramirez-Tortosa MC, Canete R, Gil A. Fasting and postprandial relationships among plasma lep-tin, ghrelin, and insulin in prepubertal obese children. Clin Nutr 2010;29:54-9.
30. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, et al. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab 2007;92:3025-32. (Pubitemid 47236366)
31. Fujimatsu D, Kotooka N, Inoue T, Nishiyama M, Node K. Association between high molecular weight adiponectin levels and metabolic parameters. J Atheroscler Thromb 2009;16:553-9.
32. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, Casano P, et al. Abdominal fat partitioning and high-molecular-weight adi-ponectin in short children born small for gestational age. J Clin Endocrinol Metab 2009;94:1049-52.
33. Willemsen RH, van Dijk M, de Rijke YB, van Toorenenbergen AW, Mulder PG, et al. Effect of growth hormone therapy on serum adiponectin and resistin levels in short, small-for-gestational-age children and associations with cardiovascular risk parameters. J Clin Endocrinol Metab 2007;92:117-23. (Pubitemid 46067518)
34. Ibáñez L, López-Bermejo A, Díaz M, Jaramillo A, Marin S, et al. Growth hormone therapy in short children born small for gestational age: effects on abdominal fat partitioning and circulating follistatin and high-molecular-weight adiponectin. J Clin Enocrinol Metab 2010;95:2234-9.